Nektar Therapeutics (NKTR) Return on Sales (2010 - 2026)

Nektar Therapeutics' Return on Sales history runs 17 years deep, the most recent figure standing at 0.04% for Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.04% in Q1 2026; TTM through Mar 2026 was 0.02%, a 1.0% decrease from a year earlier, with the FY2025 full-year figure at 0.02%, down 1.0% from the prior year.
• Return on Sales fell to 0.04% in Q1 2026 per NKTR's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q4 2024 and bottomed at 0.07% in Q2 2022.
• The 5-year median for Return on Sales is 0.02% (2023), against an average of 0.03%.
• Across the five-year window, Return on Sales retreated 14 bps in 2022 and rose 5 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2022, then sank by 292 bps to 0.02% in 2023, then soared by 162 bps to 0.01% in 2024, then slumped by 102 bps to 0.0% in 2025, then plunged by 22347 bps to 0.04% in 2026.
• Per Business Quant, the three latest NKTR Return on Sales figures stand at 0.04% (Q1 2026), 0.0% (Q4 2025), and 0.03% (Q3 2025).